Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Pancreatic cancer

RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.

SITC 2026 ESMO 202617 ASCO 2026 AACR 2026 ASH 2026

ESMO Congress 2026

23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement

The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.

Headline and verified abstracts

17 abstracts found by Parallel web research on 2026-11-11 and verified: 1 checked on the source page, 1 on a second source, 15 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.

LBA82
Late-breaking
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
Zev A. WainbergRASolute 302NCT06625320daraxonrasibchemotherapy
Verified on a second sourcecslide.ctimeetingtech.com
LBA83
Late-breaking
Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study
Eileen M. O'ReillyAMPLIFY-7PELI-002 7P
Matches source excerptcslide.ctimeetingtech.com
LBA33
Mini oral
Safety and efficacy of GFH276 monotherapy in previously treated RAS-mutated advanced solid tumors
NCT07198321GFH276
Matches source excerptcslide.ctimeetingtech.com
LBA85
Mini oral
HRS-4642 plus chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer: Preliminary results of a phase 2 study
Baiyong Shen (presented by Chenlei Wen)NCT06587061HRS-4642gemcitabinenab-paclitaxeladebrelimab
Matches source excerptcslide.ctimeetingtech.com
3136RO
Mini oral
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
AGITG MASTERPLANmFOLFIRINOXgemcitabinenab-paclitaxel
Matches source excerptcslide.ctimeetingtech.com
3137RO
Mini oral
Safety and efficacy of INCB161734, a novel oral KRAS G12D inhibitor, in combination with chemotherapy in patients (pts) with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC)
Antoine HollebecqueNCT06179160INCB161734gemcitabinenab-paclitaxelmFOLFIRINOX
Matches source excerptcslide.ctimeetingtech.com
3896RO
Mini oral
Adjunctive dronabinol for quality of life in advanced pancreatic cancer: Results of a randomized, double-blind, placebo-controlled phase III trial
NCT03984214dronabinolFOLFIRINOXgemcitabinenab-paclitaxel
Matches source excerptcslide.ctimeetingtech.com
3150P
Poster
A phase Ib/II study of HRS-4642 plus nimotuzumab in patients with KRAS G12D-mutant advanced pancreatic ductal adenocarcinoma
Dan Cao (presented by Jitao Zhou)NCT06773130HRS-4642nimotuzumab
Matches source excerptcslide.ctimeetingtech.com
3160P
Poster
Long-term clinical outcomes and immune profiling after adjuvant dendritic cell-based immunotherapy in resected pancreatic cancer: Updated REACtiVe-1 trial results
Songul KucukcelebiREACtiVe-1NCT04927780
Matches source excerptcslide.ctimeetingtech.com
3162P
Poster
Nimotuzumab plus standard adjuvant chemotherapy after curative resection for pancreatic cancer: Preliminary results of a prospective single-arm, two-cohort phase II study
Haochen TangNCT06389760nimotuzumabmFOLFIRINOXgemcitabinecapecitabine
Matches source excerptcslide.ctimeetingtech.com
3166P
Poster
Periostin (POSTN)-expressing pancreatic cancer-associated fibroblasts (CAFs) define a distinct niche associated with tumor aggressiveness and therapeutic response: Evidence from PRODIGE 24 trial
Marc HilmiPRODIGE 24NCT01526135gemcitabine
Matches source excerptcslide.ctimeetingtech.com
3178P
Poster
Precision-Panc: UK therapeutic development platform for pancreatic cancer, experience and lessons learnt (NCT04161417)
Fieke E. FroelingPRIMUSNCT04161417
Matches source excerptcslide.ctimeetingtech.com
3180P
Poster
Unveiling early-onset pancreatic cancer: Clinical, molecular and therapeutic insights from a real-world cohort
Aina De Torner Vidal
Matches source excerptcslide.ctimeetingtech.com
3184P
Poster
Safety and efficacy of PBP1510, an Anti-PAUF monoclonal antibody, in metastatic pancreatic adenocarcinoma
Daniel A. KingPAUF-IPBP1510gemcitabine
Matches source excerptcslide.ctimeetingtech.com
3190TiP
Poster
A phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations
Teresa Macarulla MercadeNCT07409272setidegrasibmFOLFIRINOXNALIRIFOX
Matches source excerptcslide.ctimeetingtech.com
3258eP
Poster
Multidimensional analysis of recurrence after curative-intent resection of pancreatic ductal adenocarcinoma
Sergio Perez-Fernandez
Matches source excerptcslide.ctimeetingtech.com
4303P
Poster
Cell-free chromatin epigenomic profiling enables non-invasive subtyping of pancreatic cancer
Verified on source page55933-bcmed.s3.amazonaws.com

Indexed in Crossref

The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.